Entera Stock Insiders

ENTX
 Stock
  

USD 1.88  0.10  5.62%   

Entera Bio employes about 21 people. The company is managed by 17 executives with total tenure of roughly 102 years, averaging almost 6.0 years of service per executive having 1.24 employees per reported executive. Break down of Entera Bio management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Entera Bio future performance.
Continue to Investing Opportunities.
  
  Adam Gridley  CEO
CEO
  Phillip Schwartz  CEO
CEO, Director
  Gerald Lieberman  Chairman
Chairman of the Board

Entera Bio Return on Sales

(23.14)

Entera Bio Management Team Effectiveness

Entera Bio has return on total asset (ROA) of (41.97) % which means that it has lost $41.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (99.97) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Invested Capital is likely to rise to 5.50 in 2022, whereas Return on Average Assets are likely to drop (0.51)  in 2022. Entera Bio Assets Non Current are fairly stable at the moment as compared to the past year. Entera Bio reported Assets Non Current of 658,000 in 2021. Goodwill and Intangible Assets is likely to rise to about 556.5 K in 2022, whereas Total Assets are likely to drop slightly above 21.9 M in 2022.

Entera Bio Quarterly Total Assets

22.31 Million

Weighted Average Shares is likely to drop to about 20.9 M in 2022. Weighted Average Shares Diluted is likely to drop to about 21.1 M in 2022

Entera Bio Workforce Comparison

Entera Bio is rated # 2 in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 128. Entera Bio retains roughly 21.0 in number of employees claiming about 16% of stocks in Biotechnology industry.

Entera Bio Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entera Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entera Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Entera Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Entera Bio Benchmark Summation

Entera Bio Notable Stakeholders

An Entera Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Entera Bio often face trade-offs trying to please all of them. Entera Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Entera Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Adam Gridley - CEOProfile
Phillip Schwartz - CEO, DirectorProfile
Gerald Lieberman - Chairman of the BoardProfile
Dana YaacovGarbeli - Interim CFOProfile
Mira Rosenzweig - CFOProfile
Hillel Galitzer - COOProfile
Miranda Toledano - Independent DirectorProfile
Sean Ellis - DirectorProfile
Gerald Ostrov - Independent DirectorProfile
Chaim Davis - DirectorProfile
David Ami - DirectorProfile
Zeev Bronfeld - DirectorProfile
Yeonatan Malca - DirectorProfile
Roger Garceau - DirectorProfile
Faith Charles - Independent DirectorProfile
Arthur Santora - Chief Medical OfficerProfile
Miriam Blum - Chief Medical OfficerProfile

About Entera Bio Management Performance

The success or failure of an entity such as Entera Bio often depends on how effective the management is. Entera Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Entera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Entera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Average Assets(0.47) (0.51) 
Return on Average Equity(0.60) (0.65) 
Return on Invested Capital 3.64  5.50 
Return on Sales(21.45) (23.14) 
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.
The data published in Entera Bio's official financial statements usually reflect Entera Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Entera Bio. For example, before you start analyzing numbers published by Entera accountants, it's critical to develop an understanding of what Entera Bio's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Entera Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entera Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Entera Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Entera Bio. Please utilize our Beneish M Score to check the likelihood of Entera Bio's management to manipulate its earnings.

Entera Bio Workforce Analysis

Traditionally, organizations such as Entera Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Entera Bio within its industry.

Entera Bio Manpower Efficiency

Return on Entera Bio Manpower

Revenue Per Employee23 K
Revenue Per Executive28.4 K
Net Loss Per Employee651.4 K
Net Loss Per Executive804.7 K
Working Capital Per Employee38.9 K
Working Capital Per Executive48.1 K
Continue to Investing Opportunities. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
-0.57
Return On Assets
-0.42
Return On Equity
-1.0
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.